Why Phreesia Stock Plummeted by 23% Today

Phreesia shares tumbled more than 23% after reporting Q3 FY2026 results that beat estimates — revenue rose 13% year-over-year to just over $120 million, active healthcare services clients increased 7% to 4,520, and the company flipped to a GAAP net profit of $4.3 million ($0.07) from a year-ago loss — with all three revenue streams growing in the low double digits (subscription +12%, network +14%, payments +11%). Management tightened full-year revenue guidance to $479–481 million (below the ~$486 million consensus) but raised adjusted EBITDA to $99–101 million from $89–92 million, a mix that appears to have prompted the sharp market reaction. While the guidance miss and a rich forward P/E (~333) create near-term valuation risk, the return to GAAP profitability and stronger EBITDA outlook signal improving fundamentals and may present a buy-on-weakness opportunity for longer-term investors.

Analysis

Phreesia reported Q3 FY2026 revenue of slightly over $120 million, up 13% year‑over‑year, beating consensus of slightly under $120 million, while active healthcare services clients increased 7% to 4,520. The company flipped to a GAAP net profit of $4.3 million ($0.07 per share) from a year‑ago loss of $14.4 million, also outperforming the break‑even bottom‑line expectation.

All three revenue streams delivered low double‑digit growth—subscription and related services +12%, network solutions +14%, and payment processing +11%—and management raised adjusted EBITDA guidance to $99–101 million from $89–92 million. Management tightened full‑year revenue guidance to $479–481 million (prior $472–482 million), which falls short of ~ $486 million analyst consensus and appears to have driven the outsized market reaction that sent the stock down more than 23%; the shares trade at a forward P/E near 333.

The beat on revenue and the return to GAAP profitability signal an operational inflection and improved margin trajectory, but the guidance miss and very rich valuation create tangible near‑term downside risk. That dynamic makes a buy‑on‑weakness stance defensible for investors with a multi‑quarter horizon, provided forthcoming revenue trends and guidance revisions are monitored closely.

Key Decisions for Investors

• Consider a staged, opportunistic buy‑on‑weakness approach — initiate or add to positions incrementally if shares decline further given the GAAP profit and higher adjusted EBITDA outlook, but keep position size modest relative to portfolio risk
• Require confirmation of top‑line stability before increasing exposure — monitor next quarter revenue versus the $479–481m FY26 guide, client growth trends, and any management guidance revisions as primary triggers to add or trim exposure
• Maintain downside protection or disciplined exits given the elevated forward P/E (~333) and recent >23% volatility — use hedges or stop limits if establishing a meaningful short‑term position